• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺炎克雷伯菌B5055的一种T7样裂解性噬菌体的特性:一种潜在的治疗剂。

Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent.

作者信息

Verma Vivek, Harjai Kusum, Chhibber Sanjay

机构信息

Department of Microbiology, Panjab University, Chandigarh, 160014, India.

出版信息

Curr Microbiol. 2009 Sep;59(3):274-81. doi: 10.1007/s00284-009-9430-y. Epub 2009 May 30.

DOI:10.1007/s00284-009-9430-y
PMID:19484297
Abstract

Characterization of bacteriophages to be used prophylactically or therapeutically is mandatory, as use of uncharacterized bacteriophages is considered as one of the major reasons of failure of phage therapy in preantibiotic era. In the present study, one lytic bacteriophage, KPO1K2, specific for Klebsiella pneumoniae B5055, with broad host range was selected for characterization. As shown by TEM, morphologically KPO1K2 possessed icosahedral head with pentagonal nature with apex to apex head diameter of about 39 nm. Presence of short noncontractile tail (10 nm) suggested its inclusion into family Podoviridae with a designation of T7-like lytic bacteriophage. The phage growth cycle with a latent period of 15 min and a burst size of approximately 140 plaque forming units per infected cell as well as a genome of 42 kbps and structural protein pattern of this bacteriophage further confirmed its T7-like characteristics. Phage was stable over a wide pH range of 4-11 and demonstrated maximum activity at 37 degrees C. After injection into mice, at 6 h, a high phage titer was seen in blood as well as in kidney and urinary bladder, though titers in kidney and urinary bladder were higher as compared to blood. Phage got cleared completely in 36 h from blood while from kidneys and urinary bladder its clearance was delayed. We propose the use of this characterized phage, KPO1K2, as a prophylactic/therapeutic agent especially for the treatment of catheter associated UTI caused by Klebsiella pneumoniae.

摘要

对用于预防或治疗的噬菌体进行特性鉴定是必不可少的,因为使用未鉴定的噬菌体被认为是噬菌体疗法在抗生素前时代失败的主要原因之一。在本研究中,选择了一种对肺炎克雷伯菌B5055具有特异性、宿主范围广泛的裂解性噬菌体KPO1K2进行特性鉴定。如透射电子显微镜所示,KPO1K2在形态上具有二十面体头部,呈五边形,顶点到顶点的头部直径约为39nm。存在短的非收缩性尾部(10nm)表明它属于短尾噬菌体科,被指定为T7样裂解性噬菌体。该噬菌体的生长周期潜伏期为15分钟,每个感染细胞的爆发量约为140个噬菌斑形成单位,以及42kbps的基因组和结构蛋白模式进一步证实了其T7样特征。噬菌体在4-11的宽pH范围内稳定,在37℃时表现出最大活性。注射到小鼠体内后,在6小时时,血液以及肾脏和膀胱中出现高噬菌体滴度,尽管肾脏和膀胱中的滴度高于血液。噬菌体在36小时内从血液中完全清除,而从肾脏和膀胱中的清除则延迟。我们建议使用这种已鉴定的噬菌体KPO1K2作为预防/治疗剂,特别是用于治疗由肺炎克雷伯菌引起的导管相关性尿路感染。

相似文献

1
Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent.肺炎克雷伯菌B5055的一种T7样裂解性噬菌体的特性:一种潜在的治疗剂。
Curr Microbiol. 2009 Sep;59(3):274-81. doi: 10.1007/s00284-009-9430-y. Epub 2009 May 30.
2
Isolation and characterization of Klebsiella pneumoniae specific bacteriophages from sewage samples.从污水样本中分离和鉴定肺炎克雷伯菌特异性噬菌体。
Folia Microbiol (Praha). 2010 May;55(3):221-7. doi: 10.1007/s12223-010-0032-7. Epub 2010 Jun 6.
3
Characterization of a virulent bacteriophage LK1 specific for Citrobacter freundii isolated from sewage water.从污水中分离出的弗氏柠檬酸杆菌特异性烈性噬菌体LK1的特性分析
J Basic Microbiol. 2014 Jun;54(6):531-41. doi: 10.1002/jobm.201200710. Epub 2013 May 20.
4
Characterising the biology of novel lytic bacteriophages infecting multidrug resistant Klebsiella pneumoniae.描述新型溶菌噬菌体感染多重耐药肺炎克雷伯菌的生物学特性。
Virol J. 2013 Mar 28;10:100. doi: 10.1186/1743-422X-10-100.
5
BVPaP-3, a T7-like lytic phage of Pseudomonas aeruginosa: its isolation and characterisation.铜绿假单胞菌 T7 样裂解噬菌体 BVPaP-3 的分离与鉴定
Curr Microbiol. 2012 Apr;64(4):305-11. doi: 10.1007/s00284-011-0071-6. Epub 2012 Jan 4.
6
Complete genome sequence of novel T7-like virus vB_KpnP_KpV289 with lytic activity against Klebsiella pneumoniae.具有针对肺炎克雷伯菌裂解活性的新型T7样病毒vB_KpnP_KpV289的全基因组序列
Arch Virol. 2016 Feb;161(2):499-501. doi: 10.1007/s00705-015-2680-z. Epub 2015 Nov 17.
7
Characterization and genome sequencing of a novel T7-like lytic phage, kpssk3, infecting carbapenem-resistant Klebsiella pneumoniae.鉴定并测序一株新型 T7 样裂解噬菌体 kpssk3,该噬菌体感染耐碳青霉烯类肺炎克雷伯菌。
Arch Virol. 2020 Jan;165(1):97-104. doi: 10.1007/s00705-019-04447-y. Epub 2019 Nov 16.
8
Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101.鉴定一种新发现的针对肺炎克雷伯菌 101 型的裂解噬菌体 vB_Kpn_F48
Viruses. 2018 Sep 9;10(9):482. doi: 10.3390/v10090482.
9
Characterization of four virulent Klebsiella pneumoniae bacteriophages, and evaluation of their potential use in complex phage preparation.鉴定四种毒力较强的肺炎克雷伯氏菌噬菌体,并评估其在复杂噬菌体制剂中的潜在应用。
Virol J. 2021 Jan 6;18(1):9. doi: 10.1186/s12985-020-01485-w.
10
Biological characteristics and genome analysis of a novel phage vB_KpnP_IME279 infecting Klebsiella pneumoniae.一种新型噬菌体 vB_KpnP_IME279 感染肺炎克雷伯菌的生物学特性及基因组分析。
Folia Microbiol (Praha). 2020 Dec;65(6):925-936. doi: 10.1007/s12223-020-00775-8. Epub 2020 Oct 16.

引用本文的文献

1
Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains of .噬菌体疗法:一种对抗……抗生素耐药菌株的可能替代疗法。 (原文此处不完整,缺少具体细菌名称)
Front Microbiol. 2025 Mar 31;16:1443430. doi: 10.3389/fmicb.2025.1443430. eCollection 2025.
2
Identification of a novel phage depolymerase against ST11 K64 carbapenem-resistant and its therapeutic potential.一种针对ST11 K64型耐碳青霉烯类细菌的新型噬菌体解聚酶的鉴定及其治疗潜力
J Bacteriol. 2025 Apr 17;207(4):e0038724. doi: 10.1128/jb.00387-24. Epub 2025 Mar 26.
3
Phage M198 and Its Therapeutic Potential.

本文引用的文献

1
Efficacy of bacteriophage treatment in murine burn wound infection induced by klebsiella pneumoniae.噬菌体治疗对肺炎克雷伯菌诱导的小鼠烧伤创面感染的疗效。
J Microbiol Biotechnol. 2009 Jun;19(6):622-8. doi: 10.4014/jmb.0808.493.
2
Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice.噬菌体治疗小鼠肺炎克雷伯菌B5055介导的大叶性肺炎的治疗潜力。
J Med Microbiol. 2008 Dec;57(Pt 12):1508-1513. doi: 10.1099/jmm.0.2008/002873-0.
3
Isolation and characterization of a T7-like lytic phage for Pseudomonas fluorescens.
噬菌体M198及其治疗潜力。
Viruses. 2025 Jan 15;17(1):115. doi: 10.3390/v17010115.
4
Specificity and diversity of Klebsiella pneumoniae phage-encoded capsule depolymerases.肺炎克雷伯菌噬菌体编码的荚膜解聚酶的特异性和多样性。
Essays Biochem. 2024 Dec 17;68(5):661-677. doi: 10.1042/EBC20240015.
5
The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.噬菌体作为抗肺炎克雷伯菌抗菌剂的潜在用途。
Virol J. 2024 Aug 19;21(1):191. doi: 10.1186/s12985-024-02450-7.
6
Engineered bacteriophages: A panacea against pathogenic and drug resistant bacteria.工程噬菌体:对抗致病性和耐药性细菌的万灵药。
Heliyon. 2024 Jul 9;10(14):e34333. doi: 10.1016/j.heliyon.2024.e34333. eCollection 2024 Jul 30.
7
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.噬菌体治疗的药代动力学和药效学:综述,重点关注多药耐药革兰氏阴性细菌感染。
Clin Microbiol Rev. 2024 Sep 12;37(3):e0004424. doi: 10.1128/cmr.00044-24. Epub 2024 Jul 29.
8
Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny.在不同抗生素类别中观察到温和噬菌体-抗生素协同作用,揭示了预防溶原性的新机制。
mBio. 2024 Jun 12;15(6):e0050424. doi: 10.1128/mbio.00504-24. Epub 2024 May 17.
9
Characterization and Preliminary Application of a Novel Lytic Bacteriophage vB_VpaP_SJSY21.新型裂解性噬菌体 vB_VpaP_SJSY21 的特性鉴定及初步应用。
Int J Mol Sci. 2023 Dec 15;24(24):17529. doi: 10.3390/ijms242417529.
10
Isolation of virulent phages against multidrug-resistant Acinetobacter baumannii recovered from inanimate objects of Jimma Medical Center, Southwest Ethiopia.从埃塞俄比亚西南部 Jimma 医疗中心的非生命物体中分离出针对多药耐药鲍曼不动杆菌的烈性噬菌体。
BMC Infect Dis. 2023 Nov 22;23(1):820. doi: 10.1186/s12879-023-08823-7.
荧光假单胞菌T7样裂解噬菌体的分离与鉴定
BMC Biotechnol. 2008 Oct 27;8:80. doi: 10.1186/1472-6750-8-80.
4
Diversity among the tailed-bacteriophages that infect the Enterobacteriaceae.感染肠杆菌科细菌的有尾噬菌体之间的多样性。
Res Microbiol. 2008 Jun;159(5):340-8. doi: 10.1016/j.resmic.2008.04.005. Epub 2008 Apr 30.
5
Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes.噬菌体制剂对内毒素刺激的多形核白细胞产生活性氧的抑制作用。
Virus Res. 2008 Feb;131(2):233-42. doi: 10.1016/j.virusres.2007.09.013. Epub 2007 Nov 9.
6
Marine viruses--major players in the global ecosystem.海洋病毒——全球生态系统中的主要参与者。
Nat Rev Microbiol. 2007 Oct;5(10):801-12. doi: 10.1038/nrmicro1750.
7
Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth.噬菌体-抗生素协同作用(PAS):β-内酰胺类和喹诺酮类抗生素刺激毒性噬菌体的生长。
PLoS One. 2007 Aug 29;2(8):e799. doi: 10.1371/journal.pone.0000799.
8
Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae.噬菌体对临床分离的多重耐药肺炎克雷伯菌所致实验性败血症小鼠的治疗作用
J Commun Dis. 2005 Mar;37(1):18-29.
9
Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients.系统评价:抗菌导尿管预防住院患者导尿管相关尿路感染
Ann Intern Med. 2006 Jan 17;144(2):116-26. doi: 10.7326/0003-4819-144-2-200601170-00009.
10
Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.口服大肠杆菌噬菌体T4的人类志愿者:噬菌体疗法的安全性测试。
Antimicrob Agents Chemother. 2005 Jul;49(7):2874-8. doi: 10.1128/AAC.49.7.2874-2878.2005.